This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
Clinical trial NCT05266014 · COMPLETED
Trial details
- NCT number
- NCT05266014
- Sponsor
- RBP4 Pty Ltd
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-12
- Primary completion
- 2023-08-15
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.